HBEGF and gastric cancer: It became evident that soluble HB-EGF (sHB-EGF) promotes tumor progression (57), and HB-EGF inhibition has been validated in vitro as a possible therapeutic target in ovarian, breast, bladder, and gastric cancer cells (58).